0001179110-14-008431.txt : 20140514 0001179110-14-008431.hdr.sgml : 20140514 20140514182737 ACCESSION NUMBER: 0001179110-14-008431 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140514 FILED AS OF DATE: 20140514 DATE AS OF CHANGE: 20140514 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Theravance Biopharma, Inc. CENTRAL INDEX KEY: 0001583107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 650-808-6000 MAIL ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THERAVANCE INC CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36033 FILM NUMBER: 14843061 BUSINESS ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508086000 MAIL ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: S. SAN FRANCISCO STATE: CA ZIP: 94080 FORMER NAME: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 3 1 edgar.xml FORM 3 - X0206 3 2014-05-14 0 0001583107 Theravance Biopharma, Inc. TBPH 0001080014 THERAVANCE INC 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 0 0 1 0 Ordinary Shares 33100000 D As of the date of this report, Theravance Biopharma, Inc. is a wholly owned subsidiary of Theravance, Inc. (NASDAQ: THRX). Theravance has announced its intention to distribute to its stockholders ordinary shares of Theravance Biopharma via a stock dividend. Any Theravance Biopharma shares held by Theravance that are not needed for the stock dividend of one Theravance Biopharma share for every 3.5 Theravance shares outstanding at the record date will be contributed by Theravance to Theravance Biopharma and will not be outstanding shares immediately following the stock dividend. Bradford J. Shafer, General Counsel and Secretary 2014-05-14